全文获取类型
收费全文 | 319篇 |
免费 | 9篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 2篇 |
基础医学 | 23篇 |
口腔科学 | 5篇 |
临床医学 | 9篇 |
内科学 | 45篇 |
神经病学 | 50篇 |
特种医学 | 18篇 |
外科学 | 75篇 |
综合类 | 1篇 |
预防医学 | 8篇 |
眼科学 | 2篇 |
药学 | 11篇 |
肿瘤学 | 76篇 |
出版年
2023年 | 5篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2018年 | 2篇 |
2017年 | 6篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 11篇 |
2013年 | 10篇 |
2012年 | 14篇 |
2011年 | 26篇 |
2010年 | 9篇 |
2009年 | 12篇 |
2008年 | 13篇 |
2007年 | 14篇 |
2006年 | 28篇 |
2005年 | 23篇 |
2004年 | 27篇 |
2003年 | 27篇 |
2002年 | 24篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 1篇 |
1998年 | 9篇 |
1997年 | 6篇 |
1996年 | 6篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1986年 | 2篇 |
1980年 | 3篇 |
排序方式: 共有329条查询结果,搜索用时 15 毫秒
61.
Kazumasa Oka Toshiki Moriyama Enyu Imai Masahiro Kyo Kiyohide Toki Toshiyuki Tanaka Masatsugu Hori Yukito Kokado Akihiko Okuyama & Shiro Takahara 《Clinical transplantation》2001,15(S5):30-34
Oka K, Moriyama T, Imai E, Kyo M, Toki K, Tanaka T, Hori M, Kokado Y, Okuyama A, Takahara S. A case of tacrolimus toxicity appearing in a second renal transplantation patient. Clin Transplantation 2001: 15 (Supplement 5): 30–34. ©Munksgaard, 2001
We experienced a case of a second renal trans- plantation patient. With the use of cyclosporin, he lost his first graft because of chronic rejection; with the use of tacrolimus, his second graft suffered from drug nephrotox- icity. On his second renal transplantation, his graft function deteriorated and required haemodialysis with the use of tacrolimus. Repeated biopsies did not reveal the typical characteristics of acute tacrolimus nephrotoxicity and acute rejection. His tacrolimus trough level was not high during the clinical course; however, by reducing tacrolimus dosage, his graft function eventually recovered to mild renal dys- function. This observation was helpful for clinical diagnosis of the functional toxicity of tacrolimus. The case is interest- ing in considering the functional toxicity of tacrolimus and the difference between tacrolimus and cyclosporin in terms of immunosuppressive and nephrotoxic actions. 相似文献
We experienced a case of a second renal trans- plantation patient. With the use of cyclosporin, he lost his first graft because of chronic rejection; with the use of tacrolimus, his second graft suffered from drug nephrotox- icity. On his second renal transplantation, his graft function deteriorated and required haemodialysis with the use of tacrolimus. Repeated biopsies did not reveal the typical characteristics of acute tacrolimus nephrotoxicity and acute rejection. His tacrolimus trough level was not high during the clinical course; however, by reducing tacrolimus dosage, his graft function eventually recovered to mild renal dys- function. This observation was helpful for clinical diagnosis of the functional toxicity of tacrolimus. The case is interest- ing in considering the functional toxicity of tacrolimus and the difference between tacrolimus and cyclosporin in terms of immunosuppressive and nephrotoxic actions. 相似文献
62.
63.
64.
Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators? 总被引:3,自引:0,他引:3
To see whether the cardiovascular profile of BRL 34915, a potent vasodilator, is characteristic of potassium channel activators, we investigated its cardiac effects by use of isolated, blood-perfused papillary muscle, sinoatrial (SA) node, and atrioventricular (AV) node preparations of dogs. BRL 34915 was injected intraarterially. It produced an increase in (coronary) blood flow in all preparations. In paced papillary muscle preparations, BRL 34915, although in large doses, produced a decrease in the force of contraction, leading nearly to abolition. The negative inotropic effect of BRL 34915 was accompanied by a marked acceleration of the repolarization of field cardiac action potentials. In some preparations, fibrillation occurred after profound negative inotropy and subsided spontaneously. In unpaced papillary muscles, BRL 34915 in large doses decreased rate of ventricular automaticity. In SA node preparations, BRL 34915 in large doses reduced sinus rate down to approximately 64% of the basal rate and produced atrial standstill in some. In AV node preparations, BRL 34915 in large doses slightly prolonged AV conduction time only when injected into the AV node artery. Nevertheless, it produced third-degree AV block in some. These cardiac effects of BRL 34915 are very similar to those of nicorandil and pinacidil, whose cardiac effects result exclusively from an increase in membrane K conductance in cardiac muscle cells. Like nicorandil and pinacidil, BRL 34915 was highly vasoselective. 相似文献
65.
Yoshihito Kogure Hideo Saka Yuichi Takiguchi Shinji Atagi Takayasu Kurata Noriyuki Ebi Akira Inoue Kaoru Kubota Mitsuhiro Takenoyama Takashi Seto Akiko Kada Takeharu Yamanaka Masahiko Ando Nobuyuki Yamamoto Akihiko Gemma Yukito Ichinose 《Clinical lung cancer》2018,19(5):e711-e715
Background
Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older.Patients and Methods
This randomized, multicenter, phase III trial (UMIN000019843) was designed to compare the efficacy and safety of CBDCA with nab-PTX with DOC in patients aged 70 years and older with advanced squamous NSCLC. Elderly patients who have received no previous chemotherapy for advanced/metastatic squamous NSCLC with Eastern Cooperative Oncology Group performance status of 0 or 1 will be randomized 1:1 to DOC (60 mg/m2 intravenous [I.V.] on day 1) or CBDCA (area under the blood concentration time curve 6 on day 1) with nab-PTX (100 mg/m2 I.V. on days 1, 8, and 15) of each 21-day cycle. The primary end point is OS. Recruitment began in December 2015 and planned enrollment is 250 patients.Conclusion
If OS is greater in patients treated with CBDCA with nab-PTX than with DOC, this study will provide a new standard of care for elderly patients with squamous NSCLC. 相似文献66.
Kazunori Nanri Shunya Takizawa Hitoshi Fujita Saori Ogawa Yukito Shinohara 《Brain research》1996,738(2):219
The purpose of the present study was to clarify the effect of topical administration of a nitric oxide synthase inhibitor on extracellular glutamate concentration in transient forebrain ischemia. Two microdialysis probes were inserted into the bilateral striata of Wistar rats. NG-Nitro-l-arginine (l-NNA) with or withoutl-arginine was topically administered into the unilateral striatum through one of the microdialysis probes, while Ringer's solution was perfused into the contralateral striatum as the control, and 14 minutes of forebrain ischemia was applied. The extracellular glutamate concentration during ischemia and subsequent reperfusion was statistically significantly higher on the 100 μMl-NNA-perfused side than on the control side, but 1 MMl-NNA was ineffective. When 100 μMl-NNA was perfused together with 500 μMl-arginine, the glutamate concentration did not differ from that on the control side. Moreover, administration of 500 μMl-arginine significantly suppressed the glutamate elevation after reperfusion. The fact that the lower dose ofl-NNA increased the accumulation of glutamate during ischemia and reperfusion without altering the blood flow may indicate that nitric oxide affords protection against ischemic neuronal damage. However, since the higher dose ofl-NNA did not affect the glutamate concentration, it appears that the effect of nitric oxide on extracellular glutamate concentration in forebrain ischemia differs, depending on the degree of the inhibition of NOS activity. 相似文献
67.
68.
Masaki Endo Yukito Abiko Syuhei Oana Norihiko Kudara Toshimi Chiba Kazuyuki Suzuki Hitohiko Koizuka Noriyuki Uesugi Tamotsu Sugai 《Digestive endoscopy》2010,22(4):360-365
In recent years, due to the increasing prevalence of upper gastrointestinal endoscopy, there have been an increasing number of reports on duodenal adenoma and early stage cancer. However, endoscopic techniques for the resection of duodenal adenomas are difficult, due to the anatomical features of the duodenum, and the long distance to the lesion. There have only been a few reports on the use of endoscopic techniques for duodenal adenomas compared to those focused on the stomach and large intestine. For duodenal adenomas, we used a conventional endoscope for lesions proximal to the major duodenal papilla, and a short‐type double balloon endoscope for lesions distal to the papilla. The en‐bloc resection rate was 93.8%. There was only one case of microperforation. Endoscopic manipulation is considered difficult in the deep areas of the duodenum, but double balloon endoscopy enabled stable manipulation and successful resection of the tumor in the majority of cases. 相似文献
69.
Noritaka Kawada Toshiki Moriyama Naotsugu Ichimaru Ryoichi Imamura Isao Matsui Yoshitsugu Takabatake Yasuyuki Nagasawa Yoshitaka Isaka Yasuyuki Kojima Yukito Kokado Hiromi Rakugi Enyu Imai Shiro Takahara 《Clinical and experimental nephrology》2009,13(4):355-360
Background
Anemia is a common complication in posttransplant patients (posttransplant anemia: PTA). We tested the hypothesis that targeting hemoglobin (Hb) over 13.3 g/dl by administration of recombinant human erythropoietin (rHuEPO-ad) has positive impact on quality of life (QOL).Methods
Twenty-four patients, whose initial Hb and estimated glomerular filtration rate (eGFR) were 10.5 ± 0.2 g/dl and 48.5 ± 2.7 ml/(min 1.73 m2), respectively, were enrolled in the present study. Physical and mental QOL in these patients before and after rHuEPO-ad were acquired and summarized as physical summary sore (PSC) and mental summary sore (MSC), respectively, by the 36-item Short Form (SF-36), an international questionnaire for analysis of QOL.Results
Before rHuEPO-ad, posttransplant patients had preserved MSC (54.1 ± 2.3) but impaired PSC (32.6 ± 3.2). rHuEPO-ad for 6 months increased their Hb to 13.7 ± 0.3 g/dl. This was accompanied by improvement of PSC (49.1 ± 2.1: P < 0.01 versus before rHuEPO-ad). MSC was preserved during rHuEPO-ad (54.4 ± 1.6: NS versus before rHuEPO-ad). There was inverse correlation between initial PSC or MSC and responses of these parameters to rHuEPO-ad (PSC, P = 0.007; MSC, P = 0.009). Patients whose initial PSC was lower than 39.6 or whose initial MSC was lower than 39.4 were expected to improve their PSC or MSC by more than 10 by rHuEPO-ad.Conclusions
Anemia in posttransplant patients has negative impacts on their QOL. Scoring mental and physical QOL by SF-36 in posttransplant patients is useful to identify groups of patients whose QOL could be improved by rHuEPO-ad. 相似文献70.
Heyan Li Koichi Takayama Shuo Wang Yoshimasa Shiraishi Keisuke Gotanda Taishi Harada Kazuto Furuyama Eiji Iwama Ichiro Ieiri Isamu Okamoto Yoichi Nakanishi 《Cancer chemotherapy and pharmacology》2014,74(6):1297-1305